Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357810 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
A Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 8
- Study locations
NCT02357810 is a Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma that has completed, run by Northwestern University. The registered enrollment target is 178 participants, above the 53-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (236% higher). The trial reports 8 study locations across 6 states.
The verdict
NCT02357810, a Phase 2 study of Recurrent Osteosarcoma and Recurrent Adult Soft Tissue Sarcoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Pazopanib Hydrochloride
- DRUG Oral Topotecan Hydrochloride
Study Locations (8)
Illinois
- Northwestern University - Chicago
- Northwestern University- Lake Forest Hospital - Lake Forest
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2015-03-21 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02357810
The ClinicalTrials.gov registry entry for NCT02357810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 53-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (236% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02357810 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Minnesota, Arizona.
Frequently Asked Questions
What is clinical trial NCT02357810 about?
NCT02357810 is a clinical study titled "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas". The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking som...
What is the current status of trial NCT02357810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2015-03-21. Estimated completion is 2021-10-12.
What conditions does trial NCT02357810 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Metastatic Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma, Recurrent Liposarcoma.
What interventions are being tested in trial NCT02357810?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pazopanib Hydrochloride (DRUG), Oral Topotecan Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02357810?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02357810 being conducted?
This trial has 8 study locations across Arizona, Florida, Illinois, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.